CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells

(2010) K. Juelke et al.   BLOOD

Human    T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement

(2010) A. Maniar et al.   BLOOD

CD137 agonist antibody prevents cancer recurrence: contribution of CD137 on both hematopoietic and nonhematopoietic cells

(2010) H. Narazaki et al.   BLOOD

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

(2010) Juan Dubrot et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

4-1BB Ligand as an Effective Multifunctional Immunomodulator and Antigen Delivery Vehicle for the Development of Therapeutic Cancer Vaccines

(2010) R. K. Sharma et al.   CANCER RESEARCH

Combination Therapy of Established Tumors by Antibodies Targeting Immune Activating and Suppressing Molecules

(2010) K. Takeda et al.   JOURNAL OF IMMUNOLOGY

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

(2009) S. P. Hilchey et al.   BLOOD

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

(2009) R. Houot et al.   BLOOD

CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells

(2009) T. Baessler et al.   BLOOD

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb

(2009) Oihana Murillo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

CD137 Promotes Proliferation and Survival of Human B Cells

(2009) X. Zhang et al.   JOURNAL OF IMMUNOLOGY

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc RI, Fc RIII, and Fc RIV

(2008) V. Minard-Colin et al.   BLOOD

Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies

(2008) W. Lin et al.   BLOOD

Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates

(2008) Nikesh Kotecha et al.   CANCER CELL

Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma

(2008) O. Murillo et al.   CLINICAL CANCER RESEARCH

Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies

(2008) Ignacio Melero et al.   TRENDS IN PHARMACOLOGICAL SCIENCES